Summary Surface Oncology Inc (Surface Oncology) is an immuno-oncology company that develops novel antibody therapies for the treatment of cancer.The company’s lead product candidate SRF231 is a human antibody that inhibits the activity of CD47, a protein overexpressed on many types of cancer cells which prevents them from being engulfed and eliminated by macrophages.
It conducts pre-clinical study through new approaches to enhance the effectiveness of antigen presentation; restrict the activity of suppressor cells in the tumor microenvironment; and to counter the effect of specific inhibitory cytokines and metabolites.Surface Oncology also provides monotherapies, checkpoint inhibitors and cancer vaccines.
The company also develops pipeline of next-generation immunotherapies that provides treatment for patients suffering from cancer. Surface Oncology is headquartered in Cambridge, Massachusetts, the US.
Surface Oncology Inc (SURF) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 220.127.116.11) - Drugs in Development, 2021 Summary Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 18.104.22.168) - Proto-oncogene serine/threonine-protein kinase Pim-1 is an enzyme encoded by the PIM1 gene. It promotes...
175 pages •
By The Business Research Company
• Jun 2021
Major players in the enzymes market are Sanofi, AbbVie Inc., Alexion Pharmaceuticals Inc, Horizon Pharma, Allergan plc, Pfizer Inc., Vivus, Digestive Care, Leadiant Biosciences, and Roche Holdings AG The global enzymes market is expected to grow from $7.81 billion in 2020 to $8.9 billion in 2021 at a compound annual growth rate (CAGR)...
TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 22.214.171.124) - Drugs in Development, 2021 Summary According to the recently published report ’TGF Beta Receptor Type 2 - Drugs in Development, 2021’; TGF Beta Receptor Type 2 (Transforming Growth Factor Beta...
Global Radiation Therapy in the Oncology Market to Reach $9,206.6 Million by 2031 Market Report Coverage - Radiation Therapy in the Oncology Market Segmentation • Radiation – External Beam Radiation, Internal Beam Radiation • Product – Oncology Systems, Particle Therapy Systems (Proton...
The global oncology biosimilars market exhibited strong growth during 2015-2020. Cancer is a lifestyle disease that occurs due to the abnormal growth of cells and may result in the formation of a tumor. At present, most of the effective cancer treatments are based on biological drugs, also known as biologics, and include...
The global interventional oncology market size is projected to reach USD 2.9 billion by 2026 from USD 1.9 billion in 2020, at a CAGR of 6.8%. Factors such as the technological advancements in the market are propelling the growth of the interventional oncology market. Additionally, rising cases of surgeries, investments from both private and...
The global generic oncology drugs market exhibited strong growth during 2015-2020. Generic oncology drugs assist in shrinking, controlling and destroying the cancer cells present in the human body. Furthermore, a few oncology drugs are widely prescribed by doctors to alleviate symptoms, including pain. They share the...
175 pages •
By The Business Research Company
• May 2021
Major players in the radiotherapy devices market are Varian Medical Systems, Elekta AB, Accuray Inc., C.R.Bard Inc., IBA Ion Beam Applications SA, Koninklijke Philips N.V., Siemens AG, Eckert & Ziegler Bebig, IsoRay Inc., and GE Healthcare. The global radiotherapy devices market is expected to grow from $5.44 billion in 2020 to $5.848...
Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 126.96.36.199) - Drugs in Development, 2021 Summary According to the recently published report ’SerineThreonine Protein Kinase Pim 2 - Drugs in Development, 2021’; Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.